Curavit Clinical Research has acquired the CRO assets of Lindus Health, expanding its clinical trial capabilities into Europe. The acquisition follows Lindus Health's shift to focus on developing its own therapeutic pipeline as Lindus Therapeutics. The combined organisation will provide life science sponsors with unified trial delivery across North America and Europe. Curavit specialises in decentralised, hybrid, and traditional clinical trials, offering services to pharma, biotech, medtech, diagnostics, and digital health companies. "Sponsors no longer have to choose between regional niche CROs or large, traditional providers when launching multi-country trials," said Joel Morse, CEO and co-founder of Curavit. The acquisition aims to accelerate site activation, improve patient recruitment, and reduce trial timelines whilst navigating international regulatory requirements.

Lindus Health and Quotient Sciences partner to accelerate drug development from first-in-human to pivotal trials. BOSTON, Dec. 11, 2025 - Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, and Quotient Sciences, a leading global clinical development and manufacturing accelerator, have announced a strategic partnership to enable innovative biotech and pharma sponsors with enhanced patient recruitment for Phase I-IIa clinical studies and a seamless pathway from first-in-human (FIH) to proof-of-concept (POC) trials. The drug development process has traditionally required companies to engage multiple vendors across pre-clinical and clinical phases, creating inefficiencies, knowledge gaps, and operational delays. Lindus Health and Quotient Sciences partnership directly addresses this industry challenge by combining Quotient's specialized early clinical and drug development capabilities with Lindus' proven patient recruitment expertise and later-stage trial delivery. The outcome is a cohesive development continuum for customers, championed by trusted, experienced partners who are agile and committed to accelerating the delivery of new treatments to patients. Quotient Sciences conducts more than 70 Phase I studies per year across its clinics in the US and UK, specializing in FIH to POC programs and a range of clinical pharmacology studies. The company's unique Translational Pharmaceutics(R) model integrates drug product development with early clinical capabilities, enabling rapid progression from formulation to FIH. Early phase studies increasingly require specific patient populations, including challenging cohorts that extend beyond traditional healthy volunteers. Through this partnership, Lindus provides comprehensive patient recruitment support with an omni-channel approach, access to over 40 million electronic medical records (EMRs), and a widespread site network. Lindus Health has an established track record of delivering 73% faster enrollment across all studies, enabling Quotient Sciences to execute efficient, high-quality Phase I-IIa trials involving patients. Lindus Health brings extensive Phase II trial experience and end-to-end trial delivery capabilities across the US, UK, and Europe, spanning multiple therapeutic areas, including respiratory, neuropsychiatry, cardiometabolic, dermatology, and more. Together, the companies offer a streamlined approach to clinical development, eliminating the need to independently source and vet separate Phase I and later-stage CROs. The result is reduced administrative burden, accelerated timelines, and more focus for sponsors on advancing their science rather than managing vendors. "This partnership underscores our commitment to removing bottlenecks in the clinical development lifecycle," said Michael Young, Co-CEO of Lindus Health. "By collaborating with Quotient Sciences, we are creating a comprehensive development pathway that allows biotech companies to move through a contiguous experience from FIH studies through to pivotal trials. Sponsors get the specialized Phase I expertise they need at the beginning, with recruitment support from the same proven end-to-end CRO partner ready to scale their programs as they progress." "Early-phase programs increasingly demand patient cohorts and rapid iteration, and Quotient is addressing this industry need. By pairing Lindus Health's recruitment engine with our early clinical development expertise and Translational Pharmaceutics(R) platform, sponsors can move seamlessly from first-in-human into later-stage trials with fewer handoffs, clearer decision-making, and materially shorter timelines," said Matt Paterson, Chief Strategy Officer, Quotient Sciences. This collaboration is essential to eliminating traditional barriers in patient recruitment and reducing friction when transitioning between development stages and CRO partners, ultimately accelerating the delivery of breakthrough treatments to patients. About Lindus Health. Lindus Health is the anti-CRO running radically faster, more reliable clinical trials for life science pioneers - bringing ground-breaking treatments to patients more quickly. By aligning incentives through fixed-price, milestone-based contracts, combining a world-class clinical operations team with a unique software platform, and leveraging access to over 40 million Electronic Health Records, Lindus Health delivers trials designed for speed, reliability, and impact. The company removes the biggest bottleneck in healthcare - clinical trials - through end-to-end study execution powered by technology and forward-thinking approaches to clinical operations. Lindus Health works with leading biotech, medical device, diagnostics, and consumer health companies to accelerate the development of innovative therapies and products. Its impact has been recognized with prestigious accolades, including the Fierce Biotech CRO Awards for Outstanding Patient Recruitment and Retention and inclusion in the PM360 Elite 100. To date, Lindus Health has delivered trials across the US, UK, and Europe in conditions ranging from diabetes and asthma to major depressive disorder, hypertension, and chronic fatigue syndrome. The company has raised over $80M from investors including Balderton, Peter Thiel, Creandum, Firstminute Capital, and Seedcamp. About Quotient Sciences. Quotient Sciences is a clinical development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, Lindus Health Limited save precious time and money in getting drugs to patients. Everything Lindus Health Limited do for its customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast, because humanity needs novel therapeutic solutions, fast. Quotient Sciences has been recognised as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023. For more information, visit quotientsciences.com.

Lindus Health named Rising Star in the 2025 Deloitte Technology Fast 50. November 13, 2025 BOSTON, NOV. 13, 2025 - Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has been awarded the Deloitte Technology Fast 50 Rising Star award. The Rising Star award is one of the five categories of the Technology Fast 50 program, which highlights the fastest-growing tech companies. The rising star winners are nominated by Deloitte and their sponsors to honor industry leaders with notable accomplishments and dedication to innovation. Lindus Health was chosen by Deloitte as a recipient of the award in the HealthTech & BioTech sector. Kiren Asad, lead partner for the Deloitte UK Technology Fast 50 programme, said, "For nearly three decades, the Fast 50 has highlighted rapidly growing and innovative technology companies across the UK. And 2025 is no different with this year's cohort having grown around 20 times on average over three years, showing that the UK tech scale-up sector is continuing to demonstrate remarkable resilience amidst global economic shifts. This prestigious recognition reflects Lindus' ongoing commitment to developing adaptive, innovative technology that fixes the broken Contract Research Organization (CRO) model through its all-in-one solution. The company drives this change through its AI-enabled approaches across the study lifecycle, and its in-house, proprietary, end-to-end trial delivery platform, Citrus(TM), ultimately accelerating timelines while delivering high-quality clinical trials. "We are honored to be among the leading tech businesses that have won this award and are proud to be recognized for our achievements in accelerating clinical research using technology," said Meri Beckwith, Co-CEO of Lindus Health. About Lindus Health. Lindus Health is the anti-CRO running radically faster, more reliable clinical trials for life science pioneers - bringing ground-breaking treatments to patients more quickly. By aligning incentives through fixed-price, milestone-based contracts, combining a world-class clinical operations team with a unique software platform, and leveraging access to over 40 million Electronic Health Records, Lindus Health delivers trials designed for speed, reliability, and impact. The company removes the biggest bottleneck in healthcare - clinical trials - through end-to-end study execution powered by technology and forward-thinking approaches to clinical operations. Lindus Health works with leading biotech, medical device, diagnostics, and consumer health companies to accelerate the development of innovative therapies and products. Its impact has been recognized with prestigious accolades, including the Fierce Biotech CRO Awards for Outstanding Patient Recruitment and Retention and inclusion in the PM360 Elite 100. To date, Lindus Health has delivered trials across the US, UK, and Europe in conditions ranging from diabetes and asthma to major depressive disorder, hypertension, and chronic fatigue syndrome. The company has raised over $80M from investors including Balderton, Peter Thiel, Creandum, Firstminute Capital, and Seedcamp. About deloitte. In this press release references to "Deloitte" are references to one or more of Deloitte Touche Tohmatsu Limited ("DTTL") a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see deloitte.com/about for a detailed description of the legal structure of DTTL and its member firms. Deloitte LLP is a subsidiary of Deloitte NSE LLP, which is a member firm of DTTL, and is among the UK's leading professional services firms. The information contained in this press release is correct at the time of going to press. For more information, please visit www.deloitte.co.uk.